Market Cap 214.08M
Revenue (ttm) 0.00
Net Income (ttm) -26.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 270,245
Avg Vol 1,695,790
Day's Range N/A - N/A
Shares Out 91.88M
Stochastic %K 54%
Beta 1.94
Analysts Strong Sell
Price Target $5.57

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 225 7416
Address:
2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States
J1476
J1476 Feb. 19 at 6:18 PM
$CNTX odd PA
0 · Reply
Gaucho2021
Gaucho2021 Feb. 18 at 6:04 PM
$CNTX What happened with the volume?!?!
1 · Reply
HiddenTicker
HiddenTicker Feb. 18 at 7:38 AM
$CNTX Context Therapeutics develops women's cancer therapies, facing early-stage pipeline with binary data and partnership-dependent future [citation:historical].
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 11:17 AM
$CNTX Current Stock Price: $2.31
0 · Reply
LabPsycho
LabPsycho Feb. 16 at 8:54 PM
$BCAB Ugh! I do not think there is a single person here, or anywhere, including me, of WTF is going on with this company: Merger? Current Cash? R/S? Reverse merger? Delisting? $CNTX relationship / milestones? A.I.? (oh now BCAB wants to do this when I offered this idea and guidance years ago!). Can anyone post a clear / tenable set of bullet points of possible outcomes.
1 · Reply
BioTechHealthX
BioTechHealthX Feb. 14 at 4:33 AM
$CNTX Context Therapeutics Inc. (NASDAQ: CNTX) did what most small-cap biotechs won’t—killed the old story and rebuilt around T cell engager bispecific antibodies for solid tumors. With a ~$223.27M market cap and leverage at 30.90%, CNTX is a classic platform re-rating candidate heading into 2026 oncology catalysts and Phase 1 data updates. https://biotechhealthx.com/biotech-news/context-cntxs-glow-up-from-old-thesis-to-t-cell-engager-chaos-in-a-good-way/
0 · Reply
MedicineMan777
MedicineMan777 Feb. 12 at 4:37 PM
$CNTX Maxim Group – Jason McCarthy, PhD • Boosted price target previously (e.g., from $4.00 → $10.00) — indicating a significant upward revision/support for CNTX’s outlook earlier in the rating cycle. 8. Piper Sandler – Biren Amin • Reiterated Overweight with targets around $4.00–$4.50, a positive stance but with more conservative price expectations relative to some peers. 9. William Blair – Matt Phipps, Ph.D. • Outperform rating and initiated coverage — generally favorable sign of confidence in long-term performance.
0 · Reply
J1476
J1476 Feb. 12 at 3:40 PM
$CNTX watching 2.60 again
0 · Reply
MedicineMan777
MedicineMan777 Feb. 11 at 2:47 PM
$CNTX 1. Cantor Fitzgerald – Li Watsek • Initiated coverage with an Overweight rating on ~Oct 2, 2025 — bullish stance implying shares should outperform the market. 2. Citizens JMP – Silvan Tuerkcan, PhD • Upgraded to Strong Buy (S. Tuerkcan) on Jan 8, 2025 — signaling high conviction in the stock’s prospects early in 2025. 3. D. Boral Capital – Jason Kolbert • Consistently reiterated Buy with a $9.00 price target in multiple updates through 2025 — among the highest bullish price targets on CNTX. 4. Guggenheim – Paul Jeng, Ph.D. • Initiated coverage at Buy with a $5.00 target on Sep 18, 2025 — positive fundamental view. 5. H.C. Wainwright & Co. – Emily Bodnar • Buy rating and has raised/lowered price targets over time (e.g., from $4 to $5 and other adjustments) — overall supportive stance with moderate targets. 6. JonesTrading – Soumit Roy, PhD • Initiated coverage with a Buy and $7.00 price target on Dec 22, 2025 — another moderately bullish call.
0 · Reply
MedicineMan777
MedicineMan777 Feb. 11 at 2:45 PM
$CNTX This is a Schedule 13G filed with the SEC by Soleus Capital, a well-known healthcare/biotech investment fund. • They own 4,776,398 shares of CNTX • That equals ~5.2% of the company • Filing date: Feb 3, 2026 • It’s a passive ownership disclosure, not an activist one
0 · Reply
Latest News on CNTX
Context Therapeutics: Undervalued Cancer Fighter

Jun 10, 2025, 7:10 AM EDT - 9 months ago

Context Therapeutics: Undervalued Cancer Fighter


Context Therapeutics Announces Chief Medical Officer Transition

May 5, 2025, 4:05 PM EDT - 10 months ago

Context Therapeutics Announces Chief Medical Officer Transition


J1476
J1476 Feb. 19 at 6:18 PM
$CNTX odd PA
0 · Reply
Gaucho2021
Gaucho2021 Feb. 18 at 6:04 PM
$CNTX What happened with the volume?!?!
1 · Reply
HiddenTicker
HiddenTicker Feb. 18 at 7:38 AM
$CNTX Context Therapeutics develops women's cancer therapies, facing early-stage pipeline with binary data and partnership-dependent future [citation:historical].
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 11:17 AM
$CNTX Current Stock Price: $2.31
0 · Reply
LabPsycho
LabPsycho Feb. 16 at 8:54 PM
$BCAB Ugh! I do not think there is a single person here, or anywhere, including me, of WTF is going on with this company: Merger? Current Cash? R/S? Reverse merger? Delisting? $CNTX relationship / milestones? A.I.? (oh now BCAB wants to do this when I offered this idea and guidance years ago!). Can anyone post a clear / tenable set of bullet points of possible outcomes.
1 · Reply
BioTechHealthX
BioTechHealthX Feb. 14 at 4:33 AM
$CNTX Context Therapeutics Inc. (NASDAQ: CNTX) did what most small-cap biotechs won’t—killed the old story and rebuilt around T cell engager bispecific antibodies for solid tumors. With a ~$223.27M market cap and leverage at 30.90%, CNTX is a classic platform re-rating candidate heading into 2026 oncology catalysts and Phase 1 data updates. https://biotechhealthx.com/biotech-news/context-cntxs-glow-up-from-old-thesis-to-t-cell-engager-chaos-in-a-good-way/
0 · Reply
MedicineMan777
MedicineMan777 Feb. 12 at 4:37 PM
$CNTX Maxim Group – Jason McCarthy, PhD • Boosted price target previously (e.g., from $4.00 → $10.00) — indicating a significant upward revision/support for CNTX’s outlook earlier in the rating cycle. 8. Piper Sandler – Biren Amin • Reiterated Overweight with targets around $4.00–$4.50, a positive stance but with more conservative price expectations relative to some peers. 9. William Blair – Matt Phipps, Ph.D. • Outperform rating and initiated coverage — generally favorable sign of confidence in long-term performance.
0 · Reply
J1476
J1476 Feb. 12 at 3:40 PM
$CNTX watching 2.60 again
0 · Reply
MedicineMan777
MedicineMan777 Feb. 11 at 2:47 PM
$CNTX 1. Cantor Fitzgerald – Li Watsek • Initiated coverage with an Overweight rating on ~Oct 2, 2025 — bullish stance implying shares should outperform the market. 2. Citizens JMP – Silvan Tuerkcan, PhD • Upgraded to Strong Buy (S. Tuerkcan) on Jan 8, 2025 — signaling high conviction in the stock’s prospects early in 2025. 3. D. Boral Capital – Jason Kolbert • Consistently reiterated Buy with a $9.00 price target in multiple updates through 2025 — among the highest bullish price targets on CNTX. 4. Guggenheim – Paul Jeng, Ph.D. • Initiated coverage at Buy with a $5.00 target on Sep 18, 2025 — positive fundamental view. 5. H.C. Wainwright & Co. – Emily Bodnar • Buy rating and has raised/lowered price targets over time (e.g., from $4 to $5 and other adjustments) — overall supportive stance with moderate targets. 6. JonesTrading – Soumit Roy, PhD • Initiated coverage with a Buy and $7.00 price target on Dec 22, 2025 — another moderately bullish call.
0 · Reply
MedicineMan777
MedicineMan777 Feb. 11 at 2:45 PM
$CNTX This is a Schedule 13G filed with the SEC by Soleus Capital, a well-known healthcare/biotech investment fund. • They own 4,776,398 shares of CNTX • That equals ~5.2% of the company • Filing date: Feb 3, 2026 • It’s a passive ownership disclosure, not an activist one
0 · Reply
MedicineMan777
MedicineMan777 Feb. 11 at 2:44 PM
$CNTX Third-party analyses (e.g., Simply Wall St and Sahm Capital) have used the reported figures to calculate that, based on recent burn rates, Context’s cash provides a runway of roughly 3-plus years, putting an informal runway into late 2027 under current spending patterns.
0 · Reply
dinnerwithme
dinnerwithme Feb. 11 at 7:50 AM
0 · Reply
RunnerSignals
RunnerSignals Feb. 10 at 9:09 PM
Market Flip: Morning dips afternoon Rockets $PLBY $IVVD $AMSC $CNTX $CNTN started in the red but flipped the board...traders buzzing, bulls grinning, bears scratching heads
0 · Reply
MedicineMan777
MedicineMan777 Feb. 10 at 12:38 PM
$CNTX Maxim Group – Jason McCarthy, PhD • Boosted price target previously (e.g., from $4.00 → $10.00) — indicating a significant upward revision/support for CNTX’s outlook earlier in the rating cycle. Piper Sandler – Biren Amin • Reiterated Overweight with targets around $4.00–$4.50, a positive stance but with more conservative price expectations relative to some peers. William Blair – Matt Phipps, Ph.D. • Outperform rating and initiated coverage — generally favorable sign of confidence in long-term performance.
0 · Reply
biovaluable
biovaluable Feb. 10 at 10:19 AM
$BCAB $CNTX remember CS202 is CAB technology by bioatla!
0 · Reply
MedicineMan777
MedicineMan777 Feb. 10 at 1:04 AM
$CNTX 1. Cantor Fitzgerald – Li Watsek • Initiated coverage with an Overweight rating on ~Oct 2, 2025 — bullish stance implying shares should outperform the market. 2. Citizens JMP – Silvan Tuerkcan, PhD • Upgraded to Strong Buy (S. Tuerkcan) on Jan 8, 2025 — signaling high conviction in the stock’s prospects early in 2025. 3. D. Boral Capital – Jason Kolbert • Consistently reiterated Buy with a $9.00 price target in multiple updates through 2025 — among the highest bullish price targets on CNTX. 4. Guggenheim – Paul Jeng, Ph.D. • Initiated coverage at Buy with a $5.00 target on Sep 18, 2025 — positive fundamental view. 5. H.C. Wainwright & Co. – Emily Bodnar • Buy rating and has raised/lowered price targets over time (e.g., from $4 to $5 and other adjustments) — overall supportive stance with moderate targets. 6. JonesTrading – Soumit Roy, PhD • Initiated coverage with a Buy and $7.00 price target on Dec 22, 2025 — another moderately bullish call.
0 · Reply
MedicineMan777
MedicineMan777 Feb. 9 at 11:13 PM
$CNTX Schedule 13G filed with the SEC by Soleus Capital, a well-known healthcare/biotech investment fund. • They own 4,776,398 shares of CNTX • That equals ~5.2% of the company • Filing date: Feb 3, 2026 • It’s a passive ownership
0 · Reply
Gaucho2021
Gaucho2021 Feb. 9 at 10:50 PM
$CNTX What happened with this? It was doing great!! Hit $2.85 and it deflated!! 😡
1 · Reply
LabPsycho
LabPsycho Feb. 9 at 8:42 PM
$CNTX Looks to me like they are setting up for a potential offering on any positive? clinical updates expected over the next several months. I am thinking easy +/- 50% move from here by June, but could probably guess that range for most of these biotechs. Good luck.
1 · Reply
MedicineMan777
MedicineMan777 Feb. 9 at 2:53 PM
$CNTX Upcoming Investor Conferences Guggenheim Emerging Outlook: Biotech Summit 2026, February 11-12, 2026, New York, NY Fireside Chat: Wednesday, February 11th at 8:30 AM ET 1x1 Meetings on February 11th TD Cowen 46th Annual Health Care Conference, March 2-4, 2026, Boston, MA Presentation: Tuesday, March 3rd at 10:30 AM ET* 1x1 Meetings on March 3rd Citizens Life Sciences Conference, March 10-11, 2026, Miami, FL Fireside Chat: Tuesday, March 10th at 11:20 AM ET 1x1 Meetings on March 10th Leerink Partners Global Healthcare Conference, March 8-11, 2026, Miami, FL Fireside Chat: Wednesday, March 11th at 9:20 AM ET* 1x1 Meetings on March 11th
0 · Reply
Nikkosi
Nikkosi Feb. 9 at 1:06 PM
$CNTX Lots of Investor Conferences coming up!!! 4 between Feb 11th to Mar 11th.
1 · Reply
dinnerwithme
dinnerwithme Feb. 9 at 12:36 PM
0 · Reply